According to international treatment guidelines, inhaled rapid-acting β2 agonists should be used for the control of symptoms in patients with asthma. We compared the efficacy and safety of an extrafine combination inhaler containing a corticosteroid (beclometasone) plus a rapid-onset, long-acting β2 agonist (formoterol) with a short-acting β2 agonist (salbutamol) as reliever strategies in patients taking beclometasone-formoterol combination as maintenance treatment.

Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial / Papi, Alberto; Corradi, Massimo; Pigeon-Francisco, Catherine; Baronio, Roberta; Siergiejko, Zenon; Petruzzelli, Stefano; Fabbri, Leonardo M; Rabe, Klaus F. - In: THE LANCET RESPIRATORY MEDICINE. - ISSN 2213-2600. - 1:1(2013), pp. 23-31. [10.1016/S2213-2600(13)70012-2]

Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial

CORRADI, Massimo;
2013

Abstract

According to international treatment guidelines, inhaled rapid-acting β2 agonists should be used for the control of symptoms in patients with asthma. We compared the efficacy and safety of an extrafine combination inhaler containing a corticosteroid (beclometasone) plus a rapid-onset, long-acting β2 agonist (formoterol) with a short-acting β2 agonist (salbutamol) as reliever strategies in patients taking beclometasone-formoterol combination as maintenance treatment.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11381/2784261
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 107
  • ???jsp.display-item.citation.isi??? 97
social impact